rs78060698 — FUT6

FUT6 rs78060698 — The Fucosylation Switch for Vitamin B12

Deep in the cells lining your small intestine, a family of enzymes called fucosyltransferases are quietly sculpting the sugar coat on your cell surfaces. These glycan structures — chains of modified sugars attached to proteins — determine which microbes can colonize your gut, how nutrients move across the intestinal wall, and how effectively your body captures vitamin B12. The FUT6 gene encodes one of these enzymes, and a single variant in its regulatory region can meaningfully shift circulating B12 levels. This variant, rs78060698, was identified in a 2017 genome-wide association study of Indian adults — a population where B12 deficiency affects an estimated 47–70% of people — and represents one of the clearest examples of how gut biology, microbial ecology, and nutrition intersect at the genetic level.

The Mechanism

FUT6 encodes alpha-1,3-fucosyltransferase 6¹¹ alpha-1,3-fucosyltransferase 6
An enzyme that transfers fucose — a six-carbon sugar — onto glycan chains on cell surfaces, creating Lewis X and sialyl-Lewis X antigens that mediate cell-cell and host-microbe recognition. These fucosylated glycans on the intestinal epithelium act as molecular docking sites for gut bacteria and influence the local microbial ecology of the small intestine.

The rs78060698 variant sits within an intron of FUT6, not in the protein-coding sequence itself. Despite its intronic location, it has clear regulatory function. Luciferase reporter assays using human HepG2 liver cells demonstrated that the A allele produces approximately 3× higher FUT6 promoter activity and 3.5–20× higher enhancer activity compared to the G allele. Electrophoretic mobility shift assays confirmed that this difference arises from differential binding of HNF4α²² HNF4α
Hepatocyte Nuclear Factor 4-alpha — a transcription factor that regulates many genes involved in glucose, lipid, and vitamin metabolism, and is a master regulator of fucosyltransferase expression: the A allele binds HNF4α with ~1.18-fold greater affinity.

The proposed pathway: higher FUT6 expression → more fucosylated glycans on intestinal epithelium → altered composition of gut microbiota → changes in bacterial production or competition for vitamin B12. Unlike its close relative FUT2, whose effects on B12 appear to operate through secretor status and H. pylori susceptibility, FUT6 genotype is associated with B12 levels independently of secretor status and H. pylori antibody titers — suggesting a distinct microbial or absorptive mechanism.

The Evidence

The primary evidence comes from a 2017 GWAS in 4,419 Indians³³ 2017 GWAS in 4,419 Indians
Nongmaithem SS et al. GWAS identifies population-specific new regulatory variants in FUT6 associated with plasma B12 concentrations in Indians. Human Molecular Genetics, 2017. The study combined a discovery cohort from the Pune Maternal Nutrition Study with three independent Indian replication cohorts. The rs78060698 A allele was associated with higher plasma B12 (beta = 0.22 on log scale, P = 8.3×10⁻¹⁷), with consistent effects across age groups and pregnancy status.

A critical population-frequency difference shapes the clinical relevance: the A allele frequency was 0.21 in Indians versus only 0.03 in Europeans (CEU panel, 1000 Genomes). This 7-fold enrichment means the variant explains substantially more B12 variance in South Asian populations than in European ones, and was likely not detected in earlier European GWAS because of its low frequency. In silico analysis confirmed the variant's functional prediction scores were significant across populations, but population-specific LD structure and effect size differences mean extrapolation to non-Indian populations requires caution.

Partial linkage disequilibrium (r² ≈ 0.54 in Indians) with a second independent FUT6 variant, rs3760775, suggests the two SNPs tag distinct but correlated regulatory signals in the same chromosomal region. Conditional analysis in the primary study confirmed rs78060698 retains independent association after adjusting for rs3760775.

Evidence is rated moderate: the association is highly significant and biologically supported by functional assays, but the causal mechanism remains proposed rather than experimentally confirmed in vivo, replication in non-Indian populations is limited, and no clinical intervention trials exist.

Practical Actions

The actionable implication of this variant is about baseline B12 monitoring and optimizing intake to compensate for genetic variation in absorptive capacity. Those with GG genotype carry no copies of the B12-boosting A allele and may have meaningfully lower circulating B12 than AG or AA counterparts — a difference that compounds with dietary insufficiency (vegetarian or vegan diets, low dairy intake) and age-related declines in gastric acid that impair B12 absorption from food.

Monitoring serum B12 — and specifically holotranscobalamin (active B12) when available — is the most direct way to determine whether genetically lower absorptive capacity translates to functional deficiency. For supplementation, methylcobalamin and adenosylcobalamin are the bioactive forms; sublingual methylcobalamin bypasses intestinal absorption steps entirely and is particularly useful when GI function is compromised.

Interactions

rs78060698 sits in the same gene cluster as rs3760775 (FUT6), which shows a slightly stronger B12 association (beta = 0.25, P = 1.2×10⁻²³) and is partially correlated (r² = 0.54 in Indians). The two variants likely tag overlapping but non-identical regulatory elements; individuals carrying both effect alleles may experience additive benefits to B12 status.

The FUT2 variants rs601338 and rs602662 operate on a related but distinct pathway (secretor status → holo-haptocorrin glycosylation → H. pylori susceptibility). Because FUT6 genotype is independent of secretor status, carrying GG at rs78060698 alongside a non-secretor FUT2 genotype represents two separate mechanisms converging on lower B12 — a combination worth tracking with serum monitoring.